GO
Loading...

Pharmaceuticals

More

  • PARIS, March 19- Sanofi's lixisenatide drug for the treatment of type 2 diabetes does not increase cardiovascular risk among high risk patients, the French drugmaker said on Thursday. Sanofi was reporting the results of a study it has been waiting to complete before seeking U.S. approval. At the time Sanofi said it would re-submit a U.S. new drug application with...

  • Charity attacks Gilead over hepatitis C drug restrictions Wednesday, 18 Mar 2015 | 4:17 PM ET

    March 18- Charity Medecins Sans Frontieres has accused U.S. drugmaker Gilead Sciences Inc of restricting access to its breakthrough hepatitis C drug Sovaldi in developing countries as it tries to protect profit margin in wealthier nations. "We're seeing Gilead trying everything it can to squeeze every last drop of profit out of some middle-income and...

  • LOS ANGELES— A judge dismissed a lawsuit by Herbalife shareholders who claimed that the business structure and marketing practices of the weight loss and nutritional supplements company violated the law and that they lost money because it amounts to a pyramid scheme. Plaintiffs did not show that accusations by activist investor Bill Ackman proved fraud by...

  • Herbalife wins dismissal of shareholder lawsuit Wednesday, 18 Mar 2015 | 11:20 AM ET
    An employee carries a box of products for shipment at the Herbalife Los Angeles distribution center in Carson, California, March 4, 2014.

    A judge dismissed a lawsuit claiming Hebalife portrayed itself as a legitimate company when it was actually an illegal pyramid scheme.

  • FDA panel to discuss Ebola vaccine development in May Wednesday, 18 Mar 2015 | 8:16 AM ET

    March 18- The U.S. Food and Drug Administration said an advisory panel will discuss the development of Ebola vaccines, days after an American health worker was flown back after being tested positive for Ebola in Sierra Leone. Ebola has so far claimed about 10,000 lives in Sierra Leone, Liberia and Guinea. Other companies that are testing potential treatments for...

  • WASHINGTON— Senate Republicans are matching President Barack Obama's proposals to cut Medicare by more than $400 billion over the coming decade, though they're not embracing his specific cuts to health care providers like hospitals and drug companies. Slated for release Wednesday afternoon, the GOP senators' companion measure contains greater cost cuts...

  • LONDON, March 17- Other big drugmakers may be reshaping their businesses but Novo Nordisk's focus on diabetes will get even bigger in the coming decade, according to the man most likely to be the Danish company's next boss. Kaare Schultz, who was made deputy chief executive in January 2014 and is the frontrunner to eventually succeed 60- year-old Lars Sorensen,...

  • *Backers include British govt, GSK, J&J, Pfizer, Lilly, Biogen. Drug companies involved include GlaxoSmithKline, Johnson& Johnson, Eli Lilly, Pfizer and Biogen Idec. The initiative, announced by Britain's health minister Jeremy Hunt at a meeting in Geneva on Tuesday, follows a Group of Eight nations conference in London in December 2013 that set a goal of finding a...

  • TRENTON, N.J.— Major drugmakers, the British government and a top Alzheimer's research charity are pooling more than $100 million to create a global fund to accelerate efforts to find a treatment or even a cure for the mind-robbing disease within a decade. Jeremy Hunt, the UK health secretary, was to announce the new fund Tuesday in Geneva at the World Health...

  • LONDON, March 17- The world's first venture capital fund dedicated to finding new ways to prevent and treat dementia has raised $100 million with the backing of the British government and several of the world's leading drugmakers. Drug companies involved include GlaxoSmithKline, Johnson& Johnson, Eli Lilly, Pfizer and Biogen Idec. The initiative, announced by...

  • BUZZ-SALIX PHARMACEUTICALS PLC: VALEANT RAISES ALL-CASH OFFER@** American drugmaker's shares up 2 pct at $173. **Canadian drugmaker Valeant Pharmaceuticals International Inc raised its offer to buy Salix to $173 from $158 in cash. **Sources told Reuters on Friday Valeant was working with its top shareholders on plans to raise its offer for Salix, sending Dublin-...

  • Valeant ups Salix bid to $11.11B and Endo ends quest Monday, 16 Mar 2015 | 8:23 AM ET

    Valeant raised its offer for Salix Pharmaceuticals Ltd. by more than $1 billion Monday, forcing rival bidder Endo International out of the running. Canada's Valeant Pharmaceuticals International Inc. said it would pay $11.11 billion in cash, or $173 per share, a 2 percent premium over Friday's closing price. On Monday, Allergan said that its acquisition by...

  • Valeant, Salix agree to cash deal of $173 a share Monday, 16 Mar 2015 | 7:56 AM ET
    Valeant Pharmaceuticals sign at the company's headquarters in Mississauga, Ontario.

    Valeant Pharmaceuticals agreed to buy Salix Pharmaceuticals for $173 per share Monday morning.

  • Heart drugs take center stage   Monday, 16 Mar 2015 | 7:21 AM ET
    Heart drugs take center stage

    CNBC's Meg Tirrell reports on which companies made the most news this weekend at the annual College of Cardiology meeting.

  • *Japan seen as among biggest beneficiaries of cheap oil. And I expect robust earnings growth to continue for the next 18-24 months, "said Tristan Hanson, head of asset allocation at Ashburton Investments in London. Mitsubishi UFJ Financial Group rose 2.0 percent and Sumitomo Mitsui Financial Group climbed 2.3 percent.

  • BUSINESS-NEWS-SCHEDULE AT 2000 GMT / 4 PM ET Sunday, 15 Mar 2015 | 4:23 PM ET

    March 15- Editor: Christian Plumb+ 1 646 223 6200. BUENOS AIRES- Argentina's economy may be stagnant but the capital city Buenos Aires is looking better than it has in years, boosting the popularity of its mayor as he prepares to run for president in October. LOS ANGELES- "Cinderella" enchants audiences this weekend, racking up a royal $70.1 million to lead the domestic...

  • NEW YORK, March 15- As drugmakers develop new medicines to battle a liver disease epidemic, they have created an urgent need for better diagnostics to select patients for treatment and assess their drugs' effectiveness. About 30 percent of people in the U.S. now suffer from fatty liver diseases, such as NASH, fueled by obesity, diabetes and over-indulgent...

  • Valeant won't overpay for Salix: Bill Ackman Friday, 13 Mar 2015 | 12:33 PM ET
    Valeant Pharmaceuticals International’s headquarters in Mississauga, Ontario, Canada, is shown in this March 30, 2011 photo.

    Valeant chief Michael Pearson won't pay too much for Salix, which earlier this week received a competing offer from Endo, Bill Ackman tells CNBC.

  • These new meds could move stocks   Friday, 13 Mar 2015 | 8:46 AM ET
    These new meds could move stocks

    CNBC's Meg Tirrell provides a preview of this weekend's American College of Cardiology meeting and the new drugs that will likely dominate the headlines.

  • March 13- Generic drugmaker Par Pharmaceutical Holdings Inc, owned by private equity firm TPG Capital, filed with U.S. regulators for an initial public offering of common stock. The major underwriters include J.P. Morgan, Goldman Sachs& Co, Citigroup and Morgan Stanley, Par Pharma said in a filing to the U. S Securities and Exchange Commission on Friday.